Purpose: mAbs are used to treat solid and hematologic malignancies and work in part through Fc receptors (FcRs) on natural killer cells (NK). However, FcR-mediated functions of NK cells from patients with cancer are significantly impaired. Identifying the mechanisms of this dysfunction and impaired response to mAb therapy could lead to combination therapies and enhance mAb therapy.

Experimental Design: Cocultures of autologous NK cells and MDSC from patients with cancer were used to study the effect of myeloid-derived suppressor cells (MDSCs) on NK-cell FcR-mediated functions including antibody-dependent cellular cytotoxicity, cytokine production, and signal transduction in vitro. Mouse breast cancer models were utilized to study the effect of MDSCs on antibody therapy in vivo and test the efficacy of combination therapies including a mAb and an MDSC-targeting agent.

Results: MDSCs from patients with cancer were found to significantly inhibit NK-cell FcR-mediated functions including antibody-dependent cellular cytotoxicity, cytokine production, and signal transduction in a contact-independent manner. In addition, adoptive transfer of MDSCs abolished the efficacy of mAb therapy in a mouse model of pancreatic cancer. Inhibition of iNOS restored NK-cell functions and signal transduction. Finally, nonspecific elimination of MDSCs or inhibition of iNOS in vivo significantly improved the efficacy of mAb therapy in a mouse model of breast cancer.

Conclusions: MDSCs antagonize NK-cell FcR-mediated function and signal transduction leading to impaired response to mAb therapy in part through nitric oxide production. Thus, elimination of MDSCs or inhibition of nitric oxide production offers a strategy to improve mAb therapy. Clin Cancer Res; 24(8); 1891–904. ©2018 AACR.

Translational Relevance

mAbs are a mainstay in the current cancer therapeutics landscape with over a dozen FDA-approved molecules used to treat solid and hematologic malignancies. One of the mechanisms of action of mAbs is the activation of the innate immune system, including NK cells, through engagement of Fc receptors including FcRγIIIA. It is also well appreciated that cancer evolves to evade the immune system in part by promoting the expansion of immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs), which are known to antagonize immune-based therapies. Understanding the impact MDSCs have on FcR-mediated NK-cell functions and the response to mAb therapy could lead to the development of novel combination therapies that enhance the efficacy of mAb therapy in multiple disease settings by eliminating or antagonizing the immunosuppressive function of MDSCs.

Natural killer (NK) cells are large granular lymphocytes that participate in innate immune responses against virus-infected and neoplastic cells via receptors for major histocompatibility antigens, markers of cellular stress (NKG2D), and immunoglobulin G (FcR; ref. 1). NK cells are unique in that they constitutively express only a low-affinity, activating FcR (FcγRIIIa or CD16), enabling them to recognize antibody (Ab)-coated targets (1, 2). FcR-activated NK cells can kill antibody-coated targets and secrete cytokines such as IFNγ and chemokines (e.g., RANTES and MIP-1α) that inhibit tumor cell proliferation, enhance antigen presentation, and promote the chemotaxis of T cells (3). These properties of FcR-activated NK cells are an important component of the response to mAb therapy (4).

NK cells are an important component of immune surveillance against the development of malignancies and the control of established tumors. NK-cell infiltration of established tumors is associated with improved disease prognosis (5, 6). However, NK cells from patients with cancer have reduced cytotoxic function and cytokine production (7). The cause of this dysfunction is not fully understood, but has been attributed to factors secreted by or expressed on the surface of tumor cells (8, 9). Only a few studies have examined the role of immunosuppressive cells in mediating NK-cell dysfunction (10, 11) in the setting of cancer.

MDSCs are immature myeloid cells with immunosuppressive properties that expand in response to tumor and stroma-derived factors (12). The frequency of circulating MDSCs correlates with tumor burden and has prognostic value (13). In mice, MDSCs are identified by expression of Gr-1 and CD11b, and in humans, they are characterized as CD33+/CD11b+/HLA-DRlow/neg (12). MDSCs inhibit T cells by a number of mechanisms including the production of free radicals, expression of amino acid–catabolizing enzymes, and the secretion of suppressive cytokines (14). Studies in murine models indicate that disruption of MDSC function can improve antitumor immune responses and impair tumor growth (15). Given the ability of MDSCs to suppress antitumor immune responses, they have received significant interest as a potential biomarker and therapeutic target (16).

Studies have shown that MDSCs impair NK-cell cytokine production and MHC-I–dependent cytotoxicity through contact-dependent mechanisms (e.g., checkpoint ligand expression and reactive oxygen species production) and contact-independent mechanisms (arginase and TGFβ production; refs. 10, 11, 17–21). However, the impact of MDSCs on NK-cell FcR-mediated function is unknown. Given the prominence of antibody therapy in the treatment of cancer, elucidation of the effects of MDSCs on FcR-mediated NK-cell function could have important clinical implications. In particular, this approach could identify novel mechanisms of resistance to mAb therapy.

It was hypothesized that MDSCs could inhibit FcR-mediated NK-cell functions and antagonize mAb therapy. Utilizing MDSCs and autologous NK cells from patients with cancer and murine models of mAb therapy, we show that MDSC nitric oxide (NO) production inhibits NK-cell FcR-mediated signal transduction and downstream effector functions including antibody dependent cellular cytotoxicity (ADCC), cytokine production, and antitumor activity in vivo. To our knowledge, this is the first report to demonstrate that MDSC-derived NO can antagonize NK-cell FcR function and blunt the response to antibody therapy.

Cell lines

EMT6, 4T1, K562, HT-29, and Raw 264.7 cells were purchased from ATCC and maintained under the recommended cell culture conditions. Panco2-EGFR+ cells were generated as described previously (22). CT26-HER and EMT6-HER2 cells were gifts from the laboratory of Dr. P.T.P. Kaumaya (Ohio State University, Columbus, OH). Cells were cultured in RPMI, Iscove's modified Dulbecco's medium, or DMEM with 10% FBS and 1% antibiotic–antimycotic.

NK and MDSC isolation

Peripheral blood from patients with cancer was obtained at the Ohio State University Comprehensive Cancer Center under Institutional Review Board approved protocols (OSU IRB Nos. 1999C0348, 2004C0096, and 2010C0036, respectively). NK cells and MDSCs were isolated by 30-minute incubation with the NK- or myeloid cell enrichment cocktail (Stem Cell Technologies) followed by Ficoll-Paque centrifugation (GE Healthcare). For MDSCs, cells were further selected using anti-HLA-DR magnetic beads for 15 minutes at 4°C and isolated using a MS-MACS column (23).

ADCC assay

Autologous NK cells and MDSCs were cocultured overnight with or without 2.5 mmol/L L-NIL. Healthy donor NK cells were treated with DMSO or 0.1 mmol/L SNAP (Sigma Aldrich) overnight. Target HT-29 tumor cells were labeled with 51Cr and then coated with cetuximab or IgG. Target cells were added to NK cells, and following a 4-hour incubation, supernatants were harvested and quantified using a gamma counter. Mean percent cell lysis was determined as described previously (2).

ELISA

Ninety-six well flat-bottom plates were coated with 100 μg/mL of polyclonal human IgG in cold PBS overnight at 4°C. NK cells, MDSC, or NK cells plus MDSC were plated at 2 × 105 cells/well as described previously (24). Where indicated, cells were treated with 2.5 mmol/L of the iNOS inhibitor L-NIL. Cell-free supernatants were harvested and analyzed for levels of IFNγ, MIP-1α, or TNF-α (ELISA; R&D Systems or eBioscience; ref. 24).

Phospho–Erk intracellular staining

Autologous NK cells and MDSC were cocultured overnight. Where indicated, cells were also treated with 2.5 mmol/L of L-NIL. The cells were incubated with the 3G8 anti-CD16 antibody (0.2 mg/mL) on ice for 30 minutes and then cross-linked with a goat anti-mouse F(ab)2 for 15 minutes. Cells were permeabilized, stained with phospho-Erk, CD56 antibodies, and analyzed by FACS (24).

Nitrotyrosine staining

NK cells were treated with 0.1 mmol/L S-Nitroso-N-acetylpenicillamine (SNAP; ref. 25). Alternatively, autologous NK cells and MDSC were cocultured overnight at a 1:1 ratio. Cells were washed with cold PBS, incubated in buffer A (Invitrogen), and permeabilized using cold methanol. Cells were stained with anti-CD16 and anti-nitrotyrosine antibodies in buffer B (Invitrogen) and analyzed by FACS.

Immunoprecipitation

NK cells were treated with SNAP as described above. Twenty micrograms of anti-nitrotyrosine beads (Millipore 16310) was added to 50 μg of protein lysate and incubated overnight at 4°C. The beads were washed with cold PBS and resuspended in 2× Laemelli buffer and boiled. The sample was loaded on a SDS gel for protein expression by immunoblot analysis. The membrane was probed with an anti-Erk antibody (Cell Signaling Technology; ref. 26).

Annexin V/PI staining

NK cells isolated from healthy donor leukopaks (American Red Cross) were treated with various concentrations of SNAP or DMSO. NK cells were stained with Annexin V and propidium iodide (PI; BD Pharmingen; ref. 23).

FACS analysis

Human MDSCs were stained with a panel of antibodies recognizing CD11b, CD33, HLA-DR, CD15, and CD14 (Beckman Coulter) as well as TIGIT ligands CD155 and CD112 (Biolegend; ref. 13). NK cells were stained using antibodies against CD16 and CD56 (BD Pharmingen). Mouse MDSCs were stained with antibodies against Gr-1 and CD11b (BD Biosciences; ref. 26). Data were acquired using a BD-LSRII and the data were analyzed using the FlowJo software.

Nitrite estimation

MDSCs were cultured in 10% human AB (HAB; Sigma Aldrich) media for 24 hours. Equal amounts of supernatant were mixed with modified Greiss reagent (Sigma Aldrich). Absorbance at 550 nm was measured using a microplate reader. Nitrite concentrations were determined using a standard curve (23).

DAF-FM staining

MDSCs were stained with 2.5 μmol/L DAFFM (Molecular probes, D-23841) for 30 minutes in serum-free media. Cells were then washed three times with serum-free media and incubated for an additional 20 minutes in RPMI complete media. Following incubation, MDSCs were washed and analyzed by FACS (27).

Mouse NK-cell isolation

Balb/c mice received single intraperitoneal injections of gemcitabine (80 mg/kg) or 5-FU (50 mg/kg). MDSC depletion was also accomplished by intraperitoneal injection of anti- Gr-1 (250 μg) daily for 5 days. To inhibit MDSC function, Balb/c mice received intraperitoneal injections of the following agents for 5 consecutive days: L-NIL (20 mg/kg), anti-TGFβ Ab (200 μg, BioXcell, clone 1D11.16.8) (28), anti-IL10 Ab (250 μg, BioXcell, clone JES5-2A5), the arginase inhibitor nor-NOHA (20 mg/kg; ref. 29) or the IDO inhibitor, 1-Methyl-d-tryptophan via oral gavage (400 mg/kg, Sigma Aldrich; ref. 30). Mice were sacrificed 24 hours after the last treatment. NK cells were isolated from the spleen using a Mouse NK Cell Enrichment Kit (Stem Cell Technologies).

Real-time PCR

Following TRIzol extraction (Invitrogen) and RNeasy purification (Qiagen), total RNA was quantitated and reverse transcribed. cDNA was used to measure gene expression by Real-Time PCR using predesigned primer/probe sets and 2× TaqMan Universal PCR Master Mix with18s rRNA as an internal control (Applied Biosystems; ref. 23).

Tumor studies

For ex vivo studies of the effect of depletion or inhibition of MDSC on NK-cell function, 4- to 5-week-old female Balb/c mice were injected with 1 × 105 4T1 mammary carcinoma cells in the mammary fat pad. For in vivo studies of the effect of depletion or inhibition of MDSC function on the response to antibody therapy, Balb/c mice were injected with 1 × 106 EMT6-HER2 mammary carcinoma cells in the mammary fat pad. MDSC transfer studies utilized immune-deficient athymic nude mice (FOXN1−/−) injected subcutaneously with 1 × 106 Panco2-EGFR+ pancreatic carcinoma cells. For the generation of MDSCs in transfer studies, Balb/c mice were injected with 1 × 105 4T1 mammary carcinoma cells, while C57BL/6 or Nos2−/− B6.129P2-Nos2tm1/Lau/J mice were injected with 1 × 105 B16F10 melanoma cells. MDSCs were isolated from the spleen using a Myeloid Derived Suppressor Cell Isolation Kit (Miltenyi Biotec). Tumor volume was measured three times weekly using digital calipers. These studies were conducted under a protocol approved by Ohio State University's Institutional Animal Care and Use Committee (IACUC 2009A0179-R2).

NK-cell depletion

Three days prior to the start of treatment, a cohort of tumor-bearing mice were injected intraperitoneally with 50-μL anti-asialo GM1 polyclonal antibody (1 mg/mL) to deplete NK cells. NK-depleted mice were administered the depleting antibody every 4 days until the end of the study. Depletion of NK cells was confirmed via flow cytometry by staining splenocytes from control and anti-asialo GM1-treated mice with an antibody against DX5.

Statistical analysis

Statistical differences between treatment groups were determined using an ANOVA model and Student t test. For murine tumor studies, a linear mixed model was employed to model longitudinal tumor volume for mice under each treatment. Comparisons were done at each time point and averaged across all time points using t statistics. The Holm–Bonferroni method was used for adjusting raw P values for multiple comparisons across treatment groups.

Study approval

Written informed consent was received from all the human participants prior to inclusion in the experimental studies under Institutional Review Board–approved protocols (OSU IRB nos. 1999C0348, 2004C0096 and 2010C0036). All mouse studies were conducted under a protocol approved by Ohio State University's Institutional Animal Care and Use Committee (IACUC 2009A0179-R2). Studies were conducted in accordance with ethical guidelines as detailed in the U.S. Common Rule.

MDSCs inhibit NK-cell cytotoxicity and ADCC

Given the ability of MDSCs to interfere with the antitumor immune responses, it was hypothesized that MDSCs could inhibit the ADCC function of NK cells. Autologous MDSCs inhibited MHC-I–dependent NK-cell cytotoxicity (K562 cytotoxicity assay), which was dose dependent, while PBMC had no effect (Supplementary Fig. S1A and S1B). The effect of MDSCs on NK-cell ADCC was tested next. MDSCs isolated from the peripheral blood of patients with melanoma (Fig. 1A; Supplementary Fig. S1C), head and neck squamous cell carcinoma (HNSCC, Fig. 1B), and breast cancer (Fig. 1C) all inhibited NK-cell ADCC function. MDSC inhibition of NK-cell ADCC reached statistical significance in the study of four melanoma patients, whereas PBMCs had no effect (Fig. 1A; Supplementary Fig. S1C). Again, the ability of MDSCs to inhibit NK-cell ADCC was dose dependent (Supplementary Fig. S1D). A phenotype of CD33+, CD11b+, and HLA-DRlow was used to identify MDSCs from melanoma patient blood draws. Before isolation, the frequency of MDSCs was 33.15% among total PBMCs and after isolation the frequency was 76% representing a 2.3-fold enrichment (Supplementary Fig. S2A and S2B). Isolated MDSCs were able to suppress T-cell proliferation (Supplementary Fig. S2C).

Figure 1.

MDSCs inhibit FcR-mediated NK-cell effector functions and signal transduction. A, NK cells from the peripheral blood of a melanoma patient were cultured alone or with autologous MDSCs overnight and then used in a 51Cr-release ADCC assay against cetuximab-coated HT-29 cells. Values represent the mean ± SD from four independent experiments, P < 0.01. Significance was determined using the paired t test. B, Results from one ADCC assay as conducted in A using NK cells and autologous MDSCs from a HNSCC patient. C, Results from one ADCC assay as conducted in A using NK cells and autologous MDSCs from a breast cancer patient. D, Autologous NK cells and MDSCs from the peripheral blood of melanoma patients were cocultured at a 1:1 ratio in 96-well plates coated with human IgG (100 μg/mL) or media (control). Supernatants were collected after 48 hours and cytokine levels measured by ELISA. Quantification of data from three independent experiments, values shown are the mean ± SE, P < 0.05. Significance was determined using a paired t test. E, Quantification of changes in p-Erk levels in FcR-activated CD56+ NK cells measured by flow cytometry in the presence or absence of MDSCs. Values are mean ± SE from eight independent experiments, P < 0.05. Significance was determined using a paired t test. F, NK cells were cultured alone, in direct contact with MDSC (Direct), or physically separated from MDSCs by a permeable 0.4-μm Corning Transwell membrane (Indirect) at a 1:1 ratio overnight. NK cells were then stimulated through the FcR using the anti-CD16 3G8 antibody and F(ab′)2 and levels of p-Erk determined as described above. Values are the mean ± SE from three independent experiments. Significance was determined using a paired t test and Holm's method. Representative flow cytometry dot plot for p-Erk is provided in Supplementary Fig. S4.

Figure 1.

MDSCs inhibit FcR-mediated NK-cell effector functions and signal transduction. A, NK cells from the peripheral blood of a melanoma patient were cultured alone or with autologous MDSCs overnight and then used in a 51Cr-release ADCC assay against cetuximab-coated HT-29 cells. Values represent the mean ± SD from four independent experiments, P < 0.01. Significance was determined using the paired t test. B, Results from one ADCC assay as conducted in A using NK cells and autologous MDSCs from a HNSCC patient. C, Results from one ADCC assay as conducted in A using NK cells and autologous MDSCs from a breast cancer patient. D, Autologous NK cells and MDSCs from the peripheral blood of melanoma patients were cocultured at a 1:1 ratio in 96-well plates coated with human IgG (100 μg/mL) or media (control). Supernatants were collected after 48 hours and cytokine levels measured by ELISA. Quantification of data from three independent experiments, values shown are the mean ± SE, P < 0.05. Significance was determined using a paired t test. E, Quantification of changes in p-Erk levels in FcR-activated CD56+ NK cells measured by flow cytometry in the presence or absence of MDSCs. Values are mean ± SE from eight independent experiments, P < 0.05. Significance was determined using a paired t test. F, NK cells were cultured alone, in direct contact with MDSC (Direct), or physically separated from MDSCs by a permeable 0.4-μm Corning Transwell membrane (Indirect) at a 1:1 ratio overnight. NK cells were then stimulated through the FcR using the anti-CD16 3G8 antibody and F(ab′)2 and levels of p-Erk determined as described above. Values are the mean ± SE from three independent experiments. Significance was determined using a paired t test and Holm's method. Representative flow cytometry dot plot for p-Erk is provided in Supplementary Fig. S4.

Close modal

MDSCs inhibit cytokine production by FcR-activated NK cells

NK cells are an important source of cytokines, such as IFNγ. Our group has shown in vitro and in phase I clinical trials that costimulation of NK cells via the FcγRIIIa and cytokines is a potent stimulus for the production of IFNγ and chemokines such as RANTES and MIP-1α (31). Therefore, the effect of MDSCs on NK-cell cytokine production was examined. Coculture of autologous MDSCs and NK cells from patients with melanoma significantly inhibited the production of IFNγ, whereas PBMC did not (Fig. 1D, P < 0.05; Supplementary Fig. S3A). This held for FcR-stimulated NK cells cultured with IL12 (Supplementary Fig. S3B). MDSC inhibition of IFNγ production was dose dependent, and a time-course experiment showed this effect was observable at 24 hours with maximal inhibition at 48 hours (Supplementary Fig. S3C and S3D). Coculture of NK cells with autologous MDSCs also significantly decreased the production of MIP-1α (Supplementary Fig. S3E, P < 0.01).

MDSCs inhibit FcR-mediated signal transduction

Erk activation is critical to NK-cell FcR-mediated effector functions and natural cytotoxicity (K562 killing). Given the impairment of these NK-cell functions in the presence of MDSCs, it was hypothesized that impaired Erk activation could lead to reduced NK-cell FcR-mediated functions following coculture with MDSCs (24). NK cells were stimulated via the FcR using the 3G8 anti-CD16 antibody and a cross-linking F(ab′)2 fragment. Measurement of p-Erk levels in CD56+ NK cells showed that coculture of melanoma patient NK cells and MDSCs resulted in a 40% decrease in p-Erk levels (Fig. 1E, P < 0.05 and representative dot plot; Supplementary Fig. S4). When NK cells were physically separated from MDSCs, levels of p-Erk in response to FcR stimulation were inhibited by an average of 28.3% (Fig. 1F, P < 0.05). When these cells were in direct contact, there was a small increase in the level of inhibition in comparison with the contact-independent condition (Fig. 1F). This result suggests that MDSC inhibition of NK-cell FcR-mediated signal transduction relies on diffusible substances with the potential for an additional contact-dependent mechanism to play a role.

Inhibition of nitric oxide production enhances NK-cell FcR-mediated function

MDSCs can promote immune suppression through several contact-independent mechanisms including expression of amino acid catabolizing enzymes, immunosuppressive cytokines, and production of nitric oxide (NO). To investigate the role of these factors in suppressing FcR-mediated NK-cell function, mice bearing 4T1 tumors were treated with neutralizing anti-IL10 (32) or anti-TGFβ (28) antibodies, or inhibitors targeting 2,3-indolamine dioxygenase (IDO; ref. 30), arginase (29), or inducible nitric oxide synthase (iNOS). NK cells were isolated from the spleen and used in ADCC assays against trastuzumab-coated CT26 cells expressing human HER2. Only inhibition of iNOS and arginase rescued NK-cell ADCC activity (Fig. 2A–C). Arginase and iNOS both use arginine as a substrate and MDSCs express high levels of both enzymes. This suggests that the arginase/iNOS arginine catabolism pathway in MDSCs plays an important role in regulating NK-cell function, and that manipulation of either pathway could impact NK-cell function. The arginase inhibitor produced a reduction in splenic MDSC frequency suggesting that the enhanced NK function in this group could reflect reduced MDSC accumulation (Supplementary Fig. S5A–S5C). Alternatively, as both arginase and iNOS utilize arginine as a common substrate, and arginine availability has been linked to NK-cell function, inhibition of either enzyme could improve NK-cell function. If this was the case, one could speculate that simultaneous inhibition of both enzymes would dramatically rescue NK-cell function. However, when this was tested, the inhibition of both enzymes was no more effective at rescuing NK-cell function than inhibition of either enzyme alone (Supplementary Fig. S5D). Together, these results suggest that the NO-arginase arginine catabolism pathway plays an important role in the regulation of NK-cell FcR-mediated functions and that iNOS is an important mediator of MDSC inhibition of NK-cell function. However, as it can be hard to draw firm conclusions from negative data obtained using neutralizing antibodies and chemical inhibitors, we concede that factors in addition to NO could still play an important role in the inhibitory effects of MDSCs.

Figure 2.

iNOS inhibition restores FcR-mediated NK-cell functions and signal transduction in the presence of MDSCs. Female Balb/c mice were inoculated with 1 × 105 4T1 tumor cells or were left uninjected (no tumor control). Following the establishment of tumors, mice were treated daily with intraperitoneal injections of IgG (250 μg), anti-TGFβ antibody (200 μg), or anti-IL10 antibody (250 μg) for four consecutive days prior to NK-cell isolation for the ADCC assay (A). The mice were sacrificed 24 hours after the last treatment. Each group consists of pooled samples from spleens of four to five mice. Values represent mean ± SD from one experiment. B, Mice were treated with PBS (vehicle), arginase inhibitor nor-NOHA (20 mg/kg) intraperitoneally or the IDO inhibitor 3-methyltryptophan (MT, 400 mg/kg) via oral gavage prior to NK-cell isolation for the ADCC assay. C, Mice were given intraperitoneal injections of PBS (vehicle) or iNOS inhibitor, L-NIL (20 mg/kg) for 1 week. NK cells isolated from the spleen were employed in a standard ADCC assay using trastuzumab-coated CT26-HER2–positive tumor cells as targets. D, NK cells and MDSCs from the peripheral blood of patients with melanoma were cocultured overnight at a 1:1 ratio with or without the nitric oxide inhibitor L-NIL (2.5 mmol/L). ADCC function of NK cells displayed as the mean percent lysis of cetuximab-coated HT-29 tumor cells at the 10:1 E:T ratio. Means ± SE from four independent experiments are shown, P < 0.05. Significance was determined using a linear mixed model. Treatment of NK cells with L-NIL alone did not enhance ADCC activity (not shown). E, Autologous NK cells and MDSC isolated from peripheral blood of melanoma patients were cocultured in 96-well plates coated with human IgG or media with or without the iNOS inhibitor L-NIL (2.5 mmol/L). Supernatants were harvested after 48 hours and analyzed for levels of IFNγ by ELISA. Values represent mean ± SE from three independent experiments, P < 0.05. Significance was determined using a linear mixed model. F, p-Erk expression in NK cells cocultured overnight with MDSC in the presence or absence of L-NIL (2.5 mmol/L). p-Erk levels are expressed as the average fold change ± SE from three independent experiments, P < 0.05. Significance was determined using a linear mixed model.

Figure 2.

iNOS inhibition restores FcR-mediated NK-cell functions and signal transduction in the presence of MDSCs. Female Balb/c mice were inoculated with 1 × 105 4T1 tumor cells or were left uninjected (no tumor control). Following the establishment of tumors, mice were treated daily with intraperitoneal injections of IgG (250 μg), anti-TGFβ antibody (200 μg), or anti-IL10 antibody (250 μg) for four consecutive days prior to NK-cell isolation for the ADCC assay (A). The mice were sacrificed 24 hours after the last treatment. Each group consists of pooled samples from spleens of four to five mice. Values represent mean ± SD from one experiment. B, Mice were treated with PBS (vehicle), arginase inhibitor nor-NOHA (20 mg/kg) intraperitoneally or the IDO inhibitor 3-methyltryptophan (MT, 400 mg/kg) via oral gavage prior to NK-cell isolation for the ADCC assay. C, Mice were given intraperitoneal injections of PBS (vehicle) or iNOS inhibitor, L-NIL (20 mg/kg) for 1 week. NK cells isolated from the spleen were employed in a standard ADCC assay using trastuzumab-coated CT26-HER2–positive tumor cells as targets. D, NK cells and MDSCs from the peripheral blood of patients with melanoma were cocultured overnight at a 1:1 ratio with or without the nitric oxide inhibitor L-NIL (2.5 mmol/L). ADCC function of NK cells displayed as the mean percent lysis of cetuximab-coated HT-29 tumor cells at the 10:1 E:T ratio. Means ± SE from four independent experiments are shown, P < 0.05. Significance was determined using a linear mixed model. Treatment of NK cells with L-NIL alone did not enhance ADCC activity (not shown). E, Autologous NK cells and MDSC isolated from peripheral blood of melanoma patients were cocultured in 96-well plates coated with human IgG or media with or without the iNOS inhibitor L-NIL (2.5 mmol/L). Supernatants were harvested after 48 hours and analyzed for levels of IFNγ by ELISA. Values represent mean ± SE from three independent experiments, P < 0.05. Significance was determined using a linear mixed model. F, p-Erk expression in NK cells cocultured overnight with MDSC in the presence or absence of L-NIL (2.5 mmol/L). p-Erk levels are expressed as the average fold change ± SE from three independent experiments, P < 0.05. Significance was determined using a linear mixed model.

Close modal

Production of nitric oxide by MDSCs is involved in the suppression of NK-cell function

To investigate the role of NO in MDSC inhibition of FcR-mediated NK-cell functions, NOS2 expression by MDSC was measured. MDSCs expressed high levels of NOS2 compared with NK and T cells (Supplementary Fig. S6A). NO production by MDSCs was detected by intracellular flow cytometry using a NO-sensitive dye 4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate (DAF-FM; Supplementary Fig. S6B), and the iNOS inhibitor L-NIL significantly inhibited NO production as measured by the Greiss reagent (Supplementary Fig. S6C, P < 0.05).

It was hypothesized that L-NIL could rescue FcR-mediated NK-cell functions in the presence of MDSC. Melanoma patient NK cells and MDSC were cocultured in the presence or absence of L-NIL, and L-NIL was found to rescue NK-cell ADCC (Fig. 2D, P < 0.01). These effects were also observed when examining the natural cytotoxicity function of NK cells (Supplementary Fig. S6D). Similarly, L-NIL rescued IFNγ production and Erk activation in the presence of MDSCs (Fig. 2E and F, P < 0.05). When NK cells and MDSCs were separated by a permeable membrane, L-NIL still rescued the generation of p-Erk supporting a predominant contact-independent mechanism (Supplementary Fig. S6E).

Nitric oxide is a negative regulator of NK-cell function

To examine the effect of NO on NK-cell function, NK cells from normal donors were incubated with a NO donor, S-Nitroso-N-Acetyl-penicillamine (SNAP, 0.1 mmol/L) or DMSO overnight in the presence or absence of IL12. SNAP significantly inhibited the ability of NK cells to lyse cetuximab-coated HT-29 colon cancer cells (Fig. 3A and B, P < 0.001). Similarly, SNAP significantly reduced the production of IFNγ (regardless of the presence of IL12; Fig. 3C, P < 0.05; Supplementary Fig. S7A). SNAP also inhibited Erk activation in FcR-stimulated NK cells (Fig. 3D, P < 0.05). Importantly, SNAP was not toxic to NK cells as the viability of SNAP-treated NK cells was >90% as measured by flow cytometry and Trypan blue exclusion (Fig. 3E and F; Supplementary Fig. S7B). In addition, SNAP did not affect the total number of NK cells remaining after treatment (Supplementary Fig. S7C). Finally, SNAP produced levels of NO that were equivalent to that produced by human MDSCs (data not shown). Together, these results suggest that NO can be a negative regulator of NK-cell FcR function.

Figure 3.

The NO donor SNAP inhibits NK-cell function and signal transduction. The nitric oxide donor SNAP inhibits NK-cell FcR-mediated function and signal transduction. A, Purified NK cells from normal donors were treated with DMSO or SNAP (0.1 mmol/L) in the presence or absence of IL12 (10 ng/mL) and then used in a 51Cr-release ADCC assay against cetuximab-coated HT-29 cells. Representative results shown are from one of three independent experiments. B, Fold change in ADCC activity of NK cells (20:1 E:T ratio) treated in a similar fashion as in A against cetuximab-coated HT-29 cells. The mean ± SE from three independent experiments are shown, P < 0.001. Significance was determined using a t test. C, Levels of IFNγ production after 48 hours measured by ELISA from healthy donor NK cells treated with DMSO or SNAP (0.1 mmol/L) and activated with immobilized IgG. Values represent mean ± SE from five independent experiments, P < 0.05. Significance was determined using a paired t test. D, Fold change in the expression of p-Erk in NK cells treated with DMSO or SNAP (0.1 mmol/L) and then stimulated through the FcR via 3G8 antibody. Values represent mean ± SE from three independent experiments, P < 0.05. Significance was determined using a paired t test. E, NK cells isolated from normal donors were treated with the indicated doses of SNAP or DMSO for 24 hours. NK cells were then stained with annexin V/PI to determine the percentage of apoptotic cells. Values displayed are from three independent experiments. F, NK cells isolated from normal donors were treated with the indicated doses of SNAP or DMSO for 24 hours. NK cells were then stained with annexin V/PI to determine the percentage of apoptotic cells. A representative flow cytometric dot plot is provided for the quantification data in E.

Figure 3.

The NO donor SNAP inhibits NK-cell function and signal transduction. The nitric oxide donor SNAP inhibits NK-cell FcR-mediated function and signal transduction. A, Purified NK cells from normal donors were treated with DMSO or SNAP (0.1 mmol/L) in the presence or absence of IL12 (10 ng/mL) and then used in a 51Cr-release ADCC assay against cetuximab-coated HT-29 cells. Representative results shown are from one of three independent experiments. B, Fold change in ADCC activity of NK cells (20:1 E:T ratio) treated in a similar fashion as in A against cetuximab-coated HT-29 cells. The mean ± SE from three independent experiments are shown, P < 0.001. Significance was determined using a t test. C, Levels of IFNγ production after 48 hours measured by ELISA from healthy donor NK cells treated with DMSO or SNAP (0.1 mmol/L) and activated with immobilized IgG. Values represent mean ± SE from five independent experiments, P < 0.05. Significance was determined using a paired t test. D, Fold change in the expression of p-Erk in NK cells treated with DMSO or SNAP (0.1 mmol/L) and then stimulated through the FcR via 3G8 antibody. Values represent mean ± SE from three independent experiments, P < 0.05. Significance was determined using a paired t test. E, NK cells isolated from normal donors were treated with the indicated doses of SNAP or DMSO for 24 hours. NK cells were then stained with annexin V/PI to determine the percentage of apoptotic cells. Values displayed are from three independent experiments. F, NK cells isolated from normal donors were treated with the indicated doses of SNAP or DMSO for 24 hours. NK cells were then stained with annexin V/PI to determine the percentage of apoptotic cells. A representative flow cytometric dot plot is provided for the quantification data in E.

Close modal

Exposure to NO leads to nitration of proteins in NK cells

Given the ability of MDSCs to inhibit Erk activation in NK cells and the ability of L-NILs to rescue this function, it was hypothesized that impaired Erk activation could be caused by nitration of signaling molecules downstream of the FcR. To investigate this, NK cells were treated with SNAP or DMSO, probed with anti-nitrotyrosine (NT) and anti-CD16 (FcR) antibodies, and analyzed by flow cytometry. SNAP treatment resulted in significant nitration of tyrosine residues on CD16+ NK cells compared with DMSO (Fig. 4A, P < 0.05). Coculture of MDSCs with NK cells also caused a significant increase in the tyrosine nitration of CD16+ NK cells (Fig. 4B, P < 0.01). Representative flow cytometry dot plots showing the change in nitrotyrosine-positive NK cells in the above two experiments are provided in Supplementary Fig. S8. Treatment of human NK cells with SNAP or coculture with MDSCs had no effect on CD16 expression (data not shown). Next, nitrotyrosine residues were immunoprecipitated from DMSO or SNAP-treated NK cells and probed for Erk. Immunoblot analysis showed that Erk was nitrated in SNAP-treated NK cells (Fig. 4C). This suggests that MDSC-derived NO results in the nitration of tyrosine residues on signaling proteins like Erk as one mechanism by which MDSC inhibit FcR-mediated NK-cell functions. With respect to the production of NO by murine MDSCs, our group has previously used IHC to show that large amounts of NO are produced by MDSCs present in the spleens of tumor-bearing mice (26). Also, it has been shown in the literature that murine MDSCs produce significant quantities of NO (12, 33).

Figure 4.

Treatment of NK cells with the NO donor SNAP or coculture with MDSCs results in nitration of tyrosine residues in NK cells. Purified NK cells from normal donors were treated with SNAP (0.01 mmol/L) or DMSO (control). Following permeablization, cells were stained with anti-CD16 and anti-nitrotyrosine antibodies and analyzed by flow cytometry. A, Representative flow cytometry profile and quantification of nitrotyrosine levels in CD16+ NK cells shown as mean fluorescence intensity (MFI; right) from three independent experiments, P < 0.05, significance was determined using a paired t test. B, Autologous NK cells and MDSC isolated from peripheral blood of melanoma patients were cocultured overnight at a ratio of 1:1 and then stained with anti-CD16 and anti-nitrotyrosine antibodies. Representative flow cytometry profile (left) and quantification of nitrotyrosine in CD16+ NK cells as mean fluorescence intensity (MFI; right) from five independent experiments, P < 0.05, significance was determined using a paired t test. C, Immunoblot showing the nitration of Erk protein. Purified NK cells from normal donors were treated with SNAP or DMSO (control), immunoprecipitated, with anti-nitrotyrosine beads and probed with anti-Erk antibody.

Figure 4.

Treatment of NK cells with the NO donor SNAP or coculture with MDSCs results in nitration of tyrosine residues in NK cells. Purified NK cells from normal donors were treated with SNAP (0.01 mmol/L) or DMSO (control). Following permeablization, cells were stained with anti-CD16 and anti-nitrotyrosine antibodies and analyzed by flow cytometry. A, Representative flow cytometry profile and quantification of nitrotyrosine levels in CD16+ NK cells shown as mean fluorescence intensity (MFI; right) from three independent experiments, P < 0.05, significance was determined using a paired t test. B, Autologous NK cells and MDSC isolated from peripheral blood of melanoma patients were cocultured overnight at a ratio of 1:1 and then stained with anti-CD16 and anti-nitrotyrosine antibodies. Representative flow cytometry profile (left) and quantification of nitrotyrosine in CD16+ NK cells as mean fluorescence intensity (MFI; right) from five independent experiments, P < 0.05, significance was determined using a paired t test. C, Immunoblot showing the nitration of Erk protein. Purified NK cells from normal donors were treated with SNAP or DMSO (control), immunoprecipitated, with anti-nitrotyrosine beads and probed with anti-Erk antibody.

Close modal

Depletion of MDSC improves NK-cell ADCC function in an animal model

Chemotherapeutic agents 5-fluorouracil (5-FU) and gemcitabine deplete MDSCs in tumor-bearing mice (34). Therefore, we investigated whether the elimination of MDSC from tumor-bearing mice could augment NK-cell function. NK cells were isolated from the spleen of mice with 4T1 mammary carcinomas 24 hours after treatment with 5-FU (50 mg/kg), gemcitabine (80 mg/kg), or PBS and used in an ADCC assay against trastuzumab-coated CT26-HER2 cells. NK cells from nontumor-bearing mice demonstrated cytotoxic activity in the range of 40% at the 25:1 effector-to-target (E:T) ratio, whereas NK cells from the PBS group exhibited cytotoxic activity of just 10%. Gemcitabine and 5-FU eliminated MDSCs from the spleens of tumor-bearing animals and this was associated with NK-cell ADCC function in the range of 30% lysis (Fig. 5A and B; Supplementary Fig. S9A and S9B). In contrast to other reports, treatment with an anti-Gr-1 antibody only modestly reduced MDSC frequency and this correlated with a slight increase in NK-cell ADCC function (Supplementary Fig. S9C and S9D). Together, these results demonstrate that MDSC in the spleen can impair NK-cell function and their elimination can augment NK-cell ADCC.

Figure 5.

Depletion of MDSC or inhibition of nitric oxide production in mice augments NK-cell–mediated ADCC activity. Female Balb/c mice were inoculated with 1 × 105 4T1 tumor cells or were left uninjected (no tumor-control). The mice were sacrificed 24 hours after treatment. NK cells isolated from the spleen were used in a standard ADCC assay using trastuzumab-coated CT26-HER2–positive tumor cells as targets. A, Mice were treated with PBS (vehicle) or gemcitabine (80 mg/kg). Graph displays mean percent lysis by pooled NK cells from four to five mice per treatment group. One of two representative experiments is shown. B, Mice were treated with PBS (vehicle) or 5-fluorouracil (50 mg/kg). Graph displays mean percent lysis by pooled NK cells from four to five mice per treatment group. One of two representative experiments is shown. C, NK cells isolated from mice treated daily for 1 week with PBS (vehicle) or iNOS inhibitor, L-NIL (20 mg/kg) were used in a standard ADCC assay using trastuzumab-coated CT26-HER2 cells. Each group consists of pooled samples from spleens of five mice. D, Fold change in NK-cell ADCC activity from mice treated as in C. Values displayed are the means ± SE from three independent experiments, P < 0.05 for the 25:1 and 12.5:1 E:T ratios. Data was log-transformed for testing group difference using a linear mixed effect model with random donor effect, and the P value was calculated using Bonferroni method. E, Female C57BL/6 (wild-type) and Nos2−/− mice were inoculated with B16F10 tumor cells or left uninjected (control). NK cells were isolated from the spleen and used in a standard ADCC assay using trastuzumab coated CT26-HER2 tumor cells. Each group consists of pooled samples from spleens of three to four mice. Values represent mean ± SD from one experiment.

Figure 5.

Depletion of MDSC or inhibition of nitric oxide production in mice augments NK-cell–mediated ADCC activity. Female Balb/c mice were inoculated with 1 × 105 4T1 tumor cells or were left uninjected (no tumor-control). The mice were sacrificed 24 hours after treatment. NK cells isolated from the spleen were used in a standard ADCC assay using trastuzumab-coated CT26-HER2–positive tumor cells as targets. A, Mice were treated with PBS (vehicle) or gemcitabine (80 mg/kg). Graph displays mean percent lysis by pooled NK cells from four to five mice per treatment group. One of two representative experiments is shown. B, Mice were treated with PBS (vehicle) or 5-fluorouracil (50 mg/kg). Graph displays mean percent lysis by pooled NK cells from four to five mice per treatment group. One of two representative experiments is shown. C, NK cells isolated from mice treated daily for 1 week with PBS (vehicle) or iNOS inhibitor, L-NIL (20 mg/kg) were used in a standard ADCC assay using trastuzumab-coated CT26-HER2 cells. Each group consists of pooled samples from spleens of five mice. D, Fold change in NK-cell ADCC activity from mice treated as in C. Values displayed are the means ± SE from three independent experiments, P < 0.05 for the 25:1 and 12.5:1 E:T ratios. Data was log-transformed for testing group difference using a linear mixed effect model with random donor effect, and the P value was calculated using Bonferroni method. E, Female C57BL/6 (wild-type) and Nos2−/− mice were inoculated with B16F10 tumor cells or left uninjected (control). NK cells were isolated from the spleen and used in a standard ADCC assay using trastuzumab coated CT26-HER2 tumor cells. Each group consists of pooled samples from spleens of three to four mice. Values represent mean ± SD from one experiment.

Close modal

Inhibition of NO in vivo enhances NK-cell–mediated ADCC activity

Next, it was investigated whether inhibition of iNOS could augment NK-cell function in vivo. Mice bearing 4T1 tumors were treated daily with PBS or the iNOS inhibitor L-NIL (20 mg/kg) for 1 week (35). NK cells isolated from the spleen were used in an ADCC assay against trastuzumab-coated CT26-HER2 cells. Treatment with L-NILs significantly improved the ADCC function of NK cells (Fig. 5C and D, P < 0.05). As seen in Supplementary Fig. S9E, there was minimal difference in the frequency of MDSCs between the PBS and NIL-treated groups.

NO generated by cancer cells has been postulated to dampen antitumor immune responses (36, 37). To delineate the role of tumor versus MDSC-derived NO, the above experiment was repeated using Nos2−/−-deficient mice. NK cells from B16F10 tumor–bearing Nos2−/− mice demonstrated normal ADCC activity compared with NK cells from wild-type B16F10 tumor-bearing mice (Fig. 5E). These results imply that host-derived and not tumor-derived NO is involved in the regulation of MDSC cell function in this tumor model.

Depletion of MDSC augments trastuzumab therapy in vivo

mAbs like trastuzumab are widely used in the treatment of cancer, and there is evidence that NK cells participate in their efficacy (38, 39). Therefore, it was hypothesized that MDSCs could antagonize mAb therapy. To this end, we employed a well-characterized EMT6 mouse model of mammary carcinoma that overexpresses human HER2 (EMT6-HER2) and responds to antibody therapy in an NK-cell–dependent manner (40). Importantly, EMT6-HER2 cells show similar growth kinetics as EMT6 parental cells and drive the expansion of MDSCs (unpublished data). Once tumors were palpable (∼50 mm3), mice were treated with PBS/IgG, 5-FU (MDSC-depleting agent), trastuzumab, or 5-FU followed by trastuzumab. Tumors of mice receiving 5-FU alone or 5-FU in combination with trastuzumab exhibited a significant decrease in MDSCs (Supplementary Fig. S10A and S10B). There was only a modest reduction in tumor volume in mice treated with trastuzumab compared with the PBS/IgG-treated control group as might be expected in a model in which the MDSC population is so prominent. Mice treated with 5-FU showed a reduction in tumor volume compared with the PBS/IgG-treated group. Importantly, 5-FU markedly enhanced the effectiveness of trastuzumab compared with either agent alone (Fig. 6A, P < 0.01 and P < 0.001, respectively). It is possible that 5-FU had a direct antitumor effect in this tumor model, but IHC staining for Ki67 and caspase-3 showed no difference in proliferation or apoptosis between these treatment groups (Supplementary Fig. S11). These results are consistent with previous studies showing 5-FU did not induce apoptosis of tumor cells or affect the prevalence of immune cells (NK and T cells) within tumors (34). We propose that one major effect of 5-FU on tumor growth is due to its actions on the MDSC compartment.

Figure 6.

MDSC antagonize mAb therapy in vivo and MDSC depletion or inhibition of NO enhances the efficacy of mAb therapy. Female Balb/c mice were inoculated with 1 × 106 EMT6-HER2 tumor cells in the mammary fat pad. Following the establishment of tumors (day 7), mice were treated once a week intraperitoneally with PBS or 5-FU and thrice weekly with IgG or trastuzumab and tumor growth was measured three times a week using digital calipers. A, Tumor growth in mice treated with PBS and IgG (10 mg/kg), 5-FU (50 mg/kg), trastuzumab (10 mg/kg), or the combination of trastuzumab plus 5-FU. Differences in tumor volumes were tested using a linear mixed model and Student t test. Values represent mean ± SE, P < 0.001. B, Tumor growth in mice treated with PBS and IgG (10 mg/kg), L-NIL (20 mg/kg), trastuzumab (10 mg/kg), or combination of trastuzumab plus L-NIL. Each group consisted of five to seven mice. Values represent mean ± SE, P < 0.005, significance was determined using a linear mixed model and Student t test. C, Depletion of NK cells with anti-asialo-GM1 abrogates the antitumor effect of trastuzumab plus NIL. Balb/c mice were inoculated with 1 × 106 EMT6-HER2 tumor cells in the mammary fat pad. Three days prior to treatment, mice were administered PBS or 50 μg/mouse of anti-asialo-GM1 polyclonal antibody to deplete NK cells. On day 8, mice were randomized and treated thrice weekly with PBS and IgG or trastuzumab (10 mg/kg) plus L-NIL (20 mg/kg). NK-depleted mice were administered the depleting antibody every 4 days until the end of the study. n = 5 for each treatment group. D, Athymic nude mice were inoculated with 1 × 106 Panco2-EGFR tumor cells on day zero. After establishment of tumors mice were injected with PBS, splenocytes, or MDSCs on day 7 prior to the initiation of treatment with IgG or cetuximab (0.5 mg/kg) on day 9. Mice were reinjected with PBS, splenocytes, or MDSCs on day 14 and IgG or cetuximab treatment was continued. D, Tumor growth curves of mice treated as described above. E, Mean tumor volume in mice inoculated with Panco2-EGFR cells before (day 7) and after treatment (day 23). Each group consisted of four to five mice. Differences in tumor volumes were tested using a linear mixed model and Student t test. Values represent mean ± SE, P < 0.001.

Figure 6.

MDSC antagonize mAb therapy in vivo and MDSC depletion or inhibition of NO enhances the efficacy of mAb therapy. Female Balb/c mice were inoculated with 1 × 106 EMT6-HER2 tumor cells in the mammary fat pad. Following the establishment of tumors (day 7), mice were treated once a week intraperitoneally with PBS or 5-FU and thrice weekly with IgG or trastuzumab and tumor growth was measured three times a week using digital calipers. A, Tumor growth in mice treated with PBS and IgG (10 mg/kg), 5-FU (50 mg/kg), trastuzumab (10 mg/kg), or the combination of trastuzumab plus 5-FU. Differences in tumor volumes were tested using a linear mixed model and Student t test. Values represent mean ± SE, P < 0.001. B, Tumor growth in mice treated with PBS and IgG (10 mg/kg), L-NIL (20 mg/kg), trastuzumab (10 mg/kg), or combination of trastuzumab plus L-NIL. Each group consisted of five to seven mice. Values represent mean ± SE, P < 0.005, significance was determined using a linear mixed model and Student t test. C, Depletion of NK cells with anti-asialo-GM1 abrogates the antitumor effect of trastuzumab plus NIL. Balb/c mice were inoculated with 1 × 106 EMT6-HER2 tumor cells in the mammary fat pad. Three days prior to treatment, mice were administered PBS or 50 μg/mouse of anti-asialo-GM1 polyclonal antibody to deplete NK cells. On day 8, mice were randomized and treated thrice weekly with PBS and IgG or trastuzumab (10 mg/kg) plus L-NIL (20 mg/kg). NK-depleted mice were administered the depleting antibody every 4 days until the end of the study. n = 5 for each treatment group. D, Athymic nude mice were inoculated with 1 × 106 Panco2-EGFR tumor cells on day zero. After establishment of tumors mice were injected with PBS, splenocytes, or MDSCs on day 7 prior to the initiation of treatment with IgG or cetuximab (0.5 mg/kg) on day 9. Mice were reinjected with PBS, splenocytes, or MDSCs on day 14 and IgG or cetuximab treatment was continued. D, Tumor growth curves of mice treated as described above. E, Mean tumor volume in mice inoculated with Panco2-EGFR cells before (day 7) and after treatment (day 23). Each group consisted of four to five mice. Differences in tumor volumes were tested using a linear mixed model and Student t test. Values represent mean ± SE, P < 0.001.

Close modal

Inhibition of MDSC NO production enhances trastuzumab therapy in vivo

Next the effect of NO inhibition on the response to trastuzumab was examined. EMT6-HER2 tumor-bearing mice were treated with PBS/IgG, L-NIL, trastuzumab or L-NIL followed by trastuzumab. No difference in tumor volume was observed between the PBS/IgG and L-NIL–treated groups, and trastuzumab modestly reduced tumor growth (Fig. 6B). However, there was a significant decrease in tumor volume when mice received NIL in combination with trastuzumab (P < 0.005, Fig. 6B). While there was a slight reduction of splenic MDSCs in treatment groups compared with the control, the frequency of tumor-infiltrating MDSC was similar indicating the observed differences in splenic MDSC frequency were likely driven by group differences in tumor volume (Supplementary Fig. S12). Importantly, the enhanced antitumor effect of the combination of trastuzumab and L-NIL was found to be NK-cell–dependent as depletion of NK cells with anti-asialo GM1 rescued tumor growth even in the setting of combination therapy (Fig. 6C; Supplementary Fig. S13A).

Transfer of MDSCs inhibits mAb therapy

To confirm the ability of MDSC to antagonize mAb therapy of cancer, an MDSC adoptive transfer experiment was performed. Athymic nude mice were inoculated with a pancreatic cancer cell line that overexpresses human HER1 (Panco2-EGFR). The parental and HER1-expressing cell lines grow at identical rates in this mouse strain and there is minimal expansion of MDSCs (unpublished data). Following the establishment of tumors, mice were injected with PBS (mock injection), splenocytes from nontumor-bearing mice, or MDSCs from syngeneic mice bearing 4T1 mammary carcinoma tumors on day 7 prior to the initiation of IgG or cetuximab therapy on day 9. A second round of cell injections was conducted on day 14 (schema shown in Supplementary Fig. S13B). Mice receiving splenocytes and cetuximab showed a significant reduction in tumor volume compared with the control group. In contrast, MDSCs ablated the effect of cetuximab therapy (Fig. 6D and E; P < 0.05).

To elucidate the role of NO production in the inhibitory effects of transferred MDSCs, a similar study was conducted using MDSC from nos2−/− deficient mice. As before, injection of wild-type MDSC abolished the antitumor effect of cetuximab therapy. However, nos2-deficeint MDSC were less antagonistic of cetuximab (Supplementary Fig. S13C). Taken together, these results demonstrate that MDSCs can dampen the antitumor response of mAb therapies and that NO production appears to play an important role in mediating this effect.

The current study provides evidence for a model in which MDSCs inhibit FcR-mediated NK-cell actions against antibody-coated tumor cells through the production of NO. The results suggest that nitration of NK-cell proteins on tyrosine residues resulted in impaired signal transduction and activation of NK cells following FcR stimulation. Elimination of MDSCs from tumor-bearing hosts or inhibition of NO production restored NK-cell effector functions and improved the anti-tumor effect of mAb therapy in vivo. Finally, transfer of wild-type MDSCs significantly antagonized mAb therapy. The results reported provide a mechanism by which MDSC-derived NO leads to impaired FcR mediated NK-cell function and reduced efficacy of mAb therapy for cancer.

NK cells play an important role in the response to mAb therapy through their ability to recognize and kill antibody-coated tumor cells via engagement of the low-affinity activating FcγRIIIa (FcR or CD16) and inhibiting metastatic spread of cancer. As a result, NK cells have received attention for their potential therapeutic and prognostic value (41). In both solid and hematologic malignancies, alterations in the frequency, maturity, and expression of activating and inhibitory receptors by NK cells have been reported that correspond with impaired NK-cell effector functions (42). While the mechanisms of this dysfunction are incompletely understood, reports have begun to explore these observations by analyzing the interaction between NK cells and cells with immunosuppressive function including MDSCs (10, 11, 18, 19, 21, 43–45).

This study provides evidence that MDSCs impair NK cell FcR-mediated functions via the production of NO and the nitration of protein tyrosine residues. Our group has previously shown that MDSC-derived NO results in nitration of key tyrosine residues on the STAT1 transcription factor resulting in impaired NK and T-cell response to IFN stimulation (26). Other groups have shown that MDSC-derived RNS can cause nitration of the T-cell receptor, thus impairing its interaction with the peptide MHC (46). In addition, RNS has been shown to cause posttranslational modification of chemokines resulting in impaired T-cell trafficking within tumors (47). Finally, tumor-derived NO has also been shown to promote immune dysfunction. Coculture of PBMCs with melanoma cell lines expressing high levels of NOS1 resulted in tyrosine nitration of T cells and monocytes. The findings that MDSC-derived NO resulted in the nitration of Erk and impaired FcR-mediated NK-cell function are the first to explore the effects of MDSCs on the NK-cell–mediated response to antitumor mAb therapy. These results further support the ability of NO to mediate immune suppression and negatively impact mAb-based treatment of cancer.

NK cells also appear to have a role in preventing metastatic spread of cancer and in the control hematologic malignancies. Notably, there are reports showing that immunosuppressive MDSC are increased in patients with leukemia (48). Our results showing that MDSCs can inhibit NK-cell natural cytotoxicity suggest that MDSCs could promote metastasis through impaired NK-cell function. Indeed, investigators have shown that MDSCs promote metastasis in the setting of breast cancer (49), but to date no report has implicated MDSC inhibition of NK-cell function in this process.

Erk is rapidly phosphorylated in primary human NK cells following FcR stimulation and this is critical to NK-cell cytokine production and ADCC (24, 50). Erk phosphorylation in FcR-stimulated NK cells was significantly inhibited by MDSCs, but this could be rescued in the presence of an iNOS inhibitor. Treatment of NK cells with the NO donor SNAP resulted in the nitration of Erk on tyrosine residues suggesting that this is one mechanism by which MDSCs inhibit Erk activation. Recently, it was identified that MDSC can inhibit p-Erk generation in NK cells through the inhibitory TIGIT receptor on NK cells (17). Analysis of NK cells and MDSCs from patients used in this work confirmed expression of these molecules. However, the ability of the iNOS inhibitor L-NIL to rescue p-Erk generation in NK cells cultured in direct contact with MDSC suggests that TIGIT may play an alternative role in this system.

Few studies have investigated the relationship between NO and NK-cell function. Earlier studies revealed that autocrine production of NO by NK cells could have a positive effect on NK-cell function, and that human NK cells appear to express endothelial NO synthase but not iNOS (51, 52). The amount of NO produced by activated NK cells is reported to be in the nanomolar range, which is substantially lower than the 2 to 20 μmol/L range of NO produced by MDSCs. This suggests that exposure to higher levels of NO produced by MDSC is detrimental to NK-cell activation and function.

In addition to producing NO, MDSCs mediate immune suppression through expression of arginase and 2,3-indoleamine dioxygenase (IDO) and inhibitory cytokines (TGFβ and IL10; ref. 12). Treatment of tumor-bearing mice with neutralizing antibodies against TGFβ and IL10 or the IDO inhibitor 1-methyl-d-tryptophan did not improve NK-cell ADCC. Nevertheless, based on studies in liver and lung cancer models, it is likely that these immunosuppressive molecules can contribute to impaired NK-cell function in vivo in other murine models and in humans (19). Notably, the arginase inhibitor nor-NOHA modestly improved NK-cell ADCC function. This finding is consistent with reports showing that depletion of L-arginine results in impaired NK-cell function (20). Arginase and iNOS utilize L-arginine as a substrate and MDSCs are known to express high levels of arginase and iNOS (12). As a result, inhibition of either could increase the availability of arginine and decrease NO generation resulting in improved NK-cell function.

The presence of immunosuppressive cells like MDSCs in the tumor microenvironment can be a major impediment to immune-based therapies (53). There are over a dozen mAbs approved by the FDA for the treatment of cancer. These agents appear to function, in part, through the activation of NK cells (4). The finding that MDSC can inhibit FcR-mediated activation and function of NK cells suggests that eliminating MDSCs or inhibiting their immunosuppressive function could also enhance mAb therapy. Recently sunitinib was found to reduce the frequency of monocytic MDSCs and their expression of arginase (54). In addition, imatinib and dasatinib were found to reduce the frequency of suppressive myeloid cells and increase the frequency of NK cells (55). Our group recently demonstrated that ibrutinib, a Bruton's tyrosine kinase inhibitor, reduced MDSCs in tumor-bearing mice and MDSC NO production (23). These results suggest that combining antibody therapy with kinase inhibitors active against MDSC could be an effective strategy. In general, strategies to deactivate or deplete MDSCs and other immunosuppressive cells could enhance the efficacy of immune-based therapies.

In summary, this report provides experimental evidence for an MDSC-mediated mechanism of action for impairment of FcR-medatied NK-cell function. MDSCs produce NO and are associated with inhibition of NK-cell ADCC, cytokine production, FcR signal transduction, and response to mAb therapy. These results suggest that mAb therapy in combination with agents targeting MDSCs could be a successful therapeutic strategy and provide a rationale for the development of clinical trials to test such combinations.

No potential conflicts of interest were disclosed.

Conception and design: A. Stiff, P. Trikha, M.A. Caligiuri, W.E. Carson

Development of methodology: A. Stiff, P. Trikha, B. Benner, N. Muthusamy, J.C. Byrd, W.E. Carson

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Stiff, P. Trikha, T.A. Mace, K. Kendra, A. Campbell, D. Abood, M.C. Duggan, R. Wesolowski, M. Old, J.H. Howard, T. Olencki, E.L. McMichael, S. Gautam, I. Landi, V. Hsu

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Stiff, P. Trikha, B.L. Mundy-Bosse, T.A. Mace, B. Benner, M.C. Duggan, M. Old, L. Yu, M.A. Caligiuri, W.E. Carson

Writing, review, and/or revision of the manuscript: A. Stiff, P. Trikha, B.L. Mundy-Bosse, T.A. Mace, B. Benner, A. Campbell, M.C. Duggan, R. Wesolowski, J.H. Howard, L. Yu, N. Muthusamy, J.C. Byrd, M.A. Caligiuri, W.E. Carson, S. Tridandapani

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A. Stiff, P. Trikha, J.H. Howard, N. Stasik

Study supervision: P. Trikha

This work was supported by NIH grants P01 CA95426, K24 CA93670 (to W.E. Carson), T32 CA90338-27, P30 CA016058, and OSUCCC Translational Therapeutics Award TT142. This work was also supported by the Pelotonia Fellowship Program.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Vivier
E
,
Raulet
DH
,
Moretta
A
,
Caligiuri
MA
,
Zitvogel
L
,
Lanier
LL
, et al
Innate or adaptive immunity? The example of natural killer cells
.
Science
2011
;
331
:
44
9
.
2.
Parihar
R
,
Dierksheide
J
,
Hu
Y
,
Carson
WE
. 
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
.
J Clin Invest
2002
;
110
:
983
92
.
3.
Roda
JM
,
Parihar
R
,
Magro
C
,
Nuovo
GJ
,
Tridandapani
S
,
Carson
WE
 III
. 
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells
.
Cancer Res
2006
;
66
:
517
26
.
4.
Scott
AM
,
Wolchok
JD
,
Old
LJ
. 
Antibody therapy of cancer
.
Nat Rev Cancer
2012
;
12
:
278
87
.
5.
Ishigami
S
,
Natsugoe
S
,
Tokuda
K
,
Nakajo
A
,
Che
X
,
Iwashige
H
, et al
Prognostic value of intratumoral natural killer cells in gastric carcinoma
.
Cancer
2000
;
88
:
577
83
.
6.
Coca
S
,
Perez-Piqueras
J
,
Martinez
D
,
Colmenarejo
A
,
Saez
MA
,
Vallejo
C
, et al
The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma
.
Cancer
1997
;
79
:
2320
8
.
7.
Costello
RT
,
Sivori
S
,
Marcenaro
E
,
Lafage-Pochitaloff
M
,
Mozziconacci
MJ
,
Reviron
D
, et al
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia
.
Blood
2002
;
99
:
3661
7
.
8.
Baginska
J
,
Viry
E
,
Paggetti
J
,
Medves
S
,
Berchem
G
,
Moussay
E
, et al
The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity
.
Front Immunol
2013
;
4
:
490
.
9.
Ashiru
O
,
Boutet
P
,
Fernandez-Messina
L
,
Aguera-Gonzalez
S
,
Skepper
JN
,
Vales-Gomez
M
, et al
Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes
.
Cancer Res
2010
;
70
:
481
9
.
10.
Cekic
C
,
Day
YJ
,
Sag
D
,
Linden
J
. 
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment
.
Cancer Res
2014
;
74
:
7250
9
.
11.
Mao
Y
,
Sarhan
D
,
Steven
A
,
Seliger
B
,
Kiessling
R
,
Lundqvist
A
. 
Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity
.
Clin Cancer Res
2014
;
20
:
4096
106
.
12.
Gabrilovich
DI
,
Nagaraj
S
. 
Myeloid-derived suppressor cells as regulators of the immune system
.
Nat Rev Immunol
2009
;
9
:
162
74
.
13.
Mundy-Bosse
BL
,
Young
GS
,
Bauer
T
,
Binkley
E
,
Bloomston
M
,
Bill
MA
, et al
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy
.
Cancer Immunol Immunother
2011
;
60
:
1269
79
.
14.
Serafini
P
,
Borrello
I
,
Bronte
V
. 
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression
.
Semin Cancer Biol
2006
;
16
:
53
65
.
15.
Youn
JI
,
Nagaraj
S
,
Collazo
M
,
Gabrilovich
DI
. 
Subsets of myeloid-derived suppressor cells in tumor-bearing mice
.
J Immunol
2008
;
181
:
5791
802
.
16.
Schneider
T
,
Sevko
A
,
Heussel
CP
,
Umansky
L
,
Beckhove
P
,
Dienemann
H
, et al
Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer
.
Clin Exp Immunol
2015
;
180
:
467
74
.
17.
Sarhan
D
,
Cichocki
F
,
Zhang
B
,
Yingst
A
,
Spellman
SR
,
Cooley
S
, et al
Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells
.
Cancer Res
2016
;
76
:
5696
706
.
18.
Hoechst
B
,
Voigtlaender
T
,
Ormandy
L
,
Gamrekelashvili
J
,
Zhao
F
,
Wedemeyer
H
, et al
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
.
Hepatology
2009
;
50
:
799
807
.
19.
Li
H
,
Han
Y
,
Guo
Q
,
Zhang
M
,
Cao
X
. 
Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1
.
J Immunol
2009
;
182
:
240
9
.
20.
Goh
CC
,
Roggerson
KM
,
Lee
HC
,
Golden-Mason
L
,
Rosen
HR
,
Hahn
YS
. 
Hepatitis C virus-induced myeloid-derived suppressor cells suppress NK cell IFN-gamma production by altering cellular metabolism via arginase-1
.
J Immunol
2016
;
196
:
2283
92
.
21.
Elkabets
M
,
Ribeiro
VS
,
Dinarello
CA
,
Ostrand-Rosenberg
S
,
Di Santo
JP
,
Apte
RN
, et al
IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function
.
Eur J Immunol
2010
;
40
:
3347
57
.
22.
McMichael
EL
,
Jaime-Ramirez
AC
,
Guenterberg
KD
,
Luedke
E
,
Atwal
LS
,
Campbell
A
, et al
IL-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells
.
Clin Cancer Res
2017
;
23
:
489
502
.
23.
Stiff
A
,
Trikha
P
,
Wesolowski
R
,
Kendra
K
,
Hsu
V
,
Uppati
S
, et al
Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment
.
Cancer Res
2016
;
76
:
2125
36
.
24.
Kondadasula
SV
,
Roda
JM
,
Parihar
R
,
Yu
J
,
Lehman
A
,
Caligiuri
MA
, et al
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma
.
Blood
2008
;
111
:
4173
83
.
25.
Lu
G
,
Zhang
R
,
Geng
S
,
Peng
L
,
Jayaraman
P
,
Chen
C
, et al
Myeloid cell-derived inducible nitric oxide synthase suppresses M1 macrophage polarization
.
Nat Commun
2015
;
6
:
6676
.
26.
Mundy-Bosse
BL
,
Lesinski
GB
,
Jaime-Ramirez
AC
,
Benninger
K
,
Khan
M
,
Kuppusamy
P
, et al
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice
.
Cancer Res
2011
;
71
:
5101
10
.
27.
Paul
DM
,
Vilas
SP
,
Kumar
JM
. 
A flow-cytometry assisted segregation of responding and non-responding population of endothelial cells for enhanced detection of intracellular nitric oxide production
.
Nitric Oxide
2011
;
25
:
31
40
.
28.
Manlove
LS
,
Berquam-Vrieze
KE
,
Pauken
KE
,
Williams
RT
,
Jenkins
MK
,
Farrar
MA
. 
Adaptive immunity to leukemia is inhibited by cross-reactive induced regulatory T cells
.
J Immunol
2015
;
195
:
4028
37
.
29.
Narita
Y
,
Kitamura
H
,
Wakita
D
,
Sumida
K
,
Masuko
K
,
Terada
S
, et al
The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice
.
J Immunol
2013
;
190
:
812
20
.
30.
Hou
DY
,
Muller
AJ
,
Sharma
MD
,
DuHadaway
J
,
Banerjee
T
,
Johnson
M
, et al
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
.
Cancer Res
2007
;
67
:
792
801
.
31.
Roda
JM
,
Joshi
T
,
Butchar
JP
,
McAlees
JW
,
Lehman
A
,
Tridandapani
S
, et al
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines
.
Clin Cancer Res
2007
;
13
:
6419
28
.
32.
Tsukamoto
H
,
Senju
S
,
Matsumura
K
,
Swain
SL
,
Nishimura
Y
. 
IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age
.
Nat Commun
2015
;
6
:
6702
.
33.
Raber
PL
,
Thevenot
P
,
Sierra
R
,
Wyczechowska
D
,
Halle
D
,
Ramirez
ME
, et al
Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways
.
Int J Cancer
2014
;
134
:
2853
64
.
34.
Vincent
J
,
Mignot
G
,
Chalmin
F
,
Ladoire
S
,
Bruchard
M
,
Chevriaux
A
, et al
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity
.
Cancer Res
2010
;
70
:
3052
61
.
35.
Schweighofer
H
,
Rummel
C
,
Mayer
K
,
Rosengarten
B
. 
Brain function in iNOS knock out or iNOS inhibited (l-NIL) mice under endotoxic shock
.
Intensive Care Med Exp
2014
;
2
:
24
.
36.
Jayaraman
P
,
Parikh
F
,
Lopez-Rivera
E
,
Hailemichael
Y
,
Clark
A
,
Ma
G
, et al
Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release
.
J Immunol
2012
;
188
:
5365
76
.
37.
Liu
Q
,
Tomei
S
,
Ascierto
ML
,
De Giorgi
V
,
Bedognetti
D
,
Dai
C
, et al
Melanoma NOS1 expression promotes dysfunctional IFN signaling
.
J Clin Invest
2014
;
124
:
2147
59
.
38.
Jaime-Ramirez
AC
,
Mundy-Bosse
BL
,
Kondadasula
S
,
Jones
NB
,
Roda
JM
,
Mani
A
, et al
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production
.
J Immunol
2011
;
186
:
3401
9
.
39.
Roda
JM
,
Parihar
R
,
Lehman
A
,
Mani
A
,
Tridandapani
S
,
Carson
WE
. 
Interleukin-21 enhances NK cell activation in response to antibody-coated targets
.
J Immunol
2006
;
177
:
120
9
.
40.
Cho
HM
,
Rosenblatt
JD
,
Tolba
K
,
Shin
SJ
,
Shin
DS
,
Calfa
C
, et al
Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response
.
Cancer Res
2010
;
70
:
10121
30
.
41.
Cheng
M
,
Chen
Y
,
Xiao
W
,
Sun
R
,
Tian
Z
. 
NK cell-based immunotherapy for malignant diseases
.
Cell Mol Immunol
2013
;
10
:
230
52
.
42.
Mamessier
E
,
Sylvain
A
,
Thibult
ML
,
Houvenaeghel
G
,
Jacquemier
J
,
Castellano
R
, et al
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
.
J Clin Invest
2011
;
121
:
3609
22
.
43.
Shime
H
,
Kojima
A
,
Maruyama
A
,
Saito
Y
,
Oshiumi
H
,
Matsumoto
M
, et al
Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models
.
J Innate Immun
2014
;
6
:
293
305
.
44.
Park
YJ
,
Song
B
,
Kim
YS
,
Kim
EK
,
Lee
JM
,
Lee
GE
, et al
Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells
.
Cancer Res
2013
;
73
:
5669
81
.
45.
Husain
Z
,
Huang
Y
,
Seth
P
,
Sukhatme
VP
. 
Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells
.
J Immunol
2013
;
191
:
1486
95
.
46.
Nagaraj
S
,
Gupta
K
,
Pisarev
V
,
Kinarsky
L
,
Sherman
S
,
Kang
L
, et al
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
.
Nat Med
2007
;
13
:
828
35
.
47.
Molon
B
,
Ugel
S
,
Del Pozzo
F
,
Soldani
C
,
Zilio
S
,
Avella
D
, et al
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
.
J Exp Med
2011
;
208
:
1949
62
.
48.
Jitschin
R
,
Braun
M
,
Buttner
M
,
Dettmer-Wilde
K
,
Bricks
J
,
Berger
J
, et al
CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
.
Blood
2014
;
124
:
750
60
.
49.
Oh
K
,
Lee
OY
,
Shon
SY
,
Nam
O
,
Ryu
PM
,
Seo
MW
, et al
A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model
.
Breast Cancer Res
2013
;
15
:
R79
.
50.
Djeu
JY
,
Jiang
K
,
Wei
S
. 
A view to a kill: signals triggering cytotoxicity
.
Clin Cancer Res
2002
;
8
:
636
40
.
51.
Furuke
K
,
Burd
PR
,
Horvath-Arcidiacono
JA
,
Hori
K
,
Mostowski
H
,
Bloom
ET
. 
Human NK cells express endothelial nitric oxide synthase, and nitric oxide protects them from activation-induced cell death by regulating expression of TNF-alpha
.
J Immunol
1999
;
163
:
1473
80
.
52.
Cifone
MG
,
D'Alo
S
,
Parroni
R
,
Millimaggi
D
,
Biordi
L
,
Martinotti
S
, et al
Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production
.
Blood
1999
;
93
:
3876
84
.
53.
Highfill
SL
,
Cui
Y
,
Giles
AJ
,
Smith
JP
,
Zhang
H
,
Morse
E
, et al
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy
.
Sci Transl Med
2014
;
6
:
237ra67
.
55.
Chen
HM
,
Ma
G
,
Gildener-Leapman
N
,
Eisenstein
S
,
Coakley
BA
,
Ozao
J
, et al
Myeloid derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy
.
Clin Cancer Res
2015
;
21
:
4073
85
.
55.
Christiansson
L
,
Soderlund
S
,
Mangsbo
S
,
Hjorth-Hansen
H
,
Hoglund
M
,
Markevarn
B
, et al
The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses
.
Mol Cancer Ther
2015
;
14
:
1181
91
.